| |
New investments in health tech have set the stage for industry players and revolutionary AI in imaging, drug discovery, digital therapeutics, and more.
Download our whitepaper for trends industry experts believe will shape the virtual care landscape. 
|
|
Today’s Big NewsSep 27, 2023 |
| By Andrea Park Philips held back more than 3,700 complaints it had received about its now-recalled respiratory devices between 2010 and the official start of the recall in mid-2021, according to an investigative report from ProPublica and the Pittsburgh Post-Gazette. |
|
|
|
By Zoey Becker After the Centers for Medicare & Medicaid Services revealed the list of drugs set to face the first round of pricing negotiations, the drugmakers responsible for marketing them are confronting a series of deadlines. |
By Nick Paul Taylor AbbVie has decided it can do without Caribou Biosciences. The Big Pharma is terminating its off-the-shelf CAR-T pact with Caribou, depriving the biotech of the chance to pocket up to $350 million in milestones per program. |
By Angus Liu Remember the groundbreaking HER2-low data for AstraZeneca and Daiichi Sankyo’s Enhertu that garnered a standing ovation at the ASCO meeting last year? England’s cost watchdog now thinks the med’s efficacy doesn’t justify its price. |
|
Tuesday, October 3, 2023 | 11am ET / 8am PT The life science industry has been growing rapidly. As a result, many biopharma companies are choosing to outsource their analytical method development and testing to CDMOs to fully meet their objectives and foster innovation. Join us to take a deep dive into these critical partnerships and learn key actionable insights. Register now. 
|
|
By Nick Paul Taylor Gilead’s $4.9 billion immuno-oncology bet has suffered another setback. An ad hoc analysis of a phase 3 leukemia trial found the anti-CD47 antibody is unlikely to improve survival, prompting the Big Biotech to stop the study. |
By Andrea Park Both brain-computer interfaces and spinal cord stimulation systems have been shown to potentially help restore arm and hand mobility after a stroke or other spinal cord injury—and, now, a system that combines the two is betting the whole is greater than the sum of its parts. |
By Kevin Dunleavy A Massachusetts federal judge has sided with Eli Lilly, overturning a $176.5 million jury verdict from November of last year. The verdict had been awarded to Teva in a patent infringement squabble over the companies’ competing migraine drugs. |
By Annalee Armstrong Ginkgo Bioworks has snared one of its biggest partners to date. The biology biotech will work with none other than Pfizer in a drug discovery deal for RNA medicines worth $331 million in biobucks for three programs. |
By Conor Hale Dubbed BigRNA, Deep Genomics' neural network is designed to predict the how RNA expression is regulated tissue-by-tissue, to better understand how variants in genes ultimately give rise to disease. |
By Fraiser Kansteiner The FDA on Wednesday approved Viatris and Ocuphire’s Ryzumvi, also known as phentolamine ophthalmic solution, to treat pharmacologically-induced mydriasis, or dilation of the pupils. The partners plan to make Ryzumvi available in the U.S. in the first half of 2024. |
By Gabrielle Masson In a reversal of fortunes, ProQR Therapeutics’ ophthalmology asset sale to Laboratoires Théa has been cancelled after ProQR failed to meet conditions of the deal. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "Podnosis," Heather Landi from Fierce Healthcare engages in a conversation with Othman Laraki, co-founder and CEO of Color Health. They delve into strategies for boosting screenings and explore the partnership between Color Health and the American Cancer Society, aimed at making convenient cancer screenings more accessible. |
|
|---|
|
|
|
Thursday, October 5, 2023 | 11am ET / 8am PT Viral vectors used in gene therapies face complex and multifaceted analytical challenges. Developing standardized and validated analytical methods, reference standards, and reagents are critical to overcoming these challenges. Join us to learn how to accelerate the development and translation of safe and effective viral vector-based gene therapies with next-generation analytics. Register now. .png)
|
|
Whitepaper As the field of real-world data and evidence is constantly evolving, it can be hard to keep-up with best practices. Do you know the definitive characteristics of a high-quality dataset? What questions to ask if you decide to outsource your research to consultants? Here’s everything you need to know in one, must-have guide. Sponsored by: MarketScan by Merative |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper Learn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper 15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| |
|
